Neurologic crises in hereditary tyrosinemia

Abstract

Hereditary tyrosinemia results from an inborn error in the final step of tyrosine metabolism. The disease is known to cause acute and chronic liver failure, renal Fanconi's syndrome, and hepatocellular carcinoma. Neurologic manifestations have been reported but not emphasized as a common problem. In this paper, we describe neurologic crises that occurred among children identified as having tyrosinemia on neonatal screening since 1970. Of the 48 children with tyrosinemia, 20 (42 percent) had neurologic crises that began at a mean age of one year and led to 104 hospital admissions. These abrupt episodes of peripheral neuropathy were characterized by severe pain with extensor hypertonia (in 75 percent), vomiting or paralytic ileus (69 percent), muscle weakness (29 percent), and self-mutilation (8 percent). Eight children required mechanical ventilation because of paralysis, and 14 of the 20 children have died. Between crises, most survivors regained normal function. We found no reliable biochemical marker for the crises (those we evaluated included blood levels of tyrosine, succinylacetone, and hepatic aminotransferases). Urinary excretion of delta-aminolevulinic acid, a neurotoxic intermediate of porphyrin biosynthesis, was elevated during crises but also during the asymptomatic periods. Electrophysiologic studies in seven patients and neuromuscular biopsies in three patients showed axonal degeneration and secondary demyelination. We conclude that episodes of acute, severe peripheral neuropathy are common in hereditary tyrosinemia and resemble the crises of the neuropathic porphyrias.


Source Information

Department of Genetics, Hopital Sainte Justine, Montreal, PQ, Canada.




This article has been cited by other articles:


Nakamura, K., Tanaka, Y., Mitsubuchi, H., Endo, F. (2007). Animal Models of Tyrosinemia. J. Nutr. 137: 1556S-1560S [Abstract] [Full Text]
Burns, T. M., Ryan, M. M., Darras, B., Jones, H. R. Jr (2003). Current Therapeutic Strategies for Patients With Polyneuropathies Secondary to Inherited Metabolic Disorders. Mayo Clin Proc. 78: 858-868 [Abstract]
Evans, A. (2002). An Infant with Otitis Media and Abdominal Distension. CLIN PEDIATR 41: 537-541
Aponte, J. L., Sega, G. A., Hauser, L. J., Dhar, M. S., Withrow, C. M., Carpenter, D. A., Rinchik, E. M., Culiat, C. T., Johnson, D. K. (2001). Point mutations in the murine fumarylacetoacetate hydrolase gene: Animal models for the human genetic disorder hereditary tyrosinemia type 1. Proc. Natl. Acad. Sci. USA 98: 641-645 [Abstract] [Full Text]
Mitchell, G. (1996). Bad guy makes good: Inhibition of 4-Hydroxyphenylpyruvate Dioxygenase by 2-(2-Nitro-4-trifluoromethyl benzoyl)-cyclohexane-1,3-dione and 2-(2-Chloro-4- methanesulfonylbenzoyl)-cyclohexane-1,3-dione Ellis MK, Whitfield AC, Gowans LA, Auton TR, McLean Provan W, Lock EA and Smith LL Toxicology and Applied Pharmacology, 1995; 133: 12-19. Hum Exp Toxicol 15: 179-181
Grompe, M., St.-Louis, M., Demers, S. I., Al-Dhalimy, M., Leclerc, B., Tanguay, R. M. (1994). A Single Mutation of the Fumarylacetoacetate Hydrolase Gene in French Canadians with Hereditary Tyrosinemia Type I. NEJM 331: 353-357 [Abstract] [Full Text]
Grompe, M, al-Dhalimy, M, Finegold, M, Ou, C N, Burlingame, T, Kennaway, N G, Soriano, P (1993). Loss of fumarylacetoacetate hydrolase is responsible for the neonatal hepatic dysfunction phenotype of lethal albino mice.. Genes Dev. 7: 2298-2307 [Abstract]
Bateman, R. L., Bhanumoorthy, P., Witte, J. F., McClard, R. W., Grompe, M., Timm, D. E. (2001). Mechanistic Inferences from the Crystal Structure of Fumarylacetoacetate Hydrolase with a Bound Phosphorus-based Inhibitor. J. Biol. Chem. 276: 15284-15291 [Abstract] [Full Text]